Radcliffe Cardiology

A virtual event by Radcliffe Cardiology

Rhythm Interventions Online

The world's largest virtual arrhythmia event

Content for healthcare professionals only

Symposium – Next Era of Cardiac Ablation: Optimising Outcomes in Clinical Practice

This symposium is supported by Medtronic. Agenda

  • 00:20: Welcome and Introduction – Reza Wakili

  • 01:42: PFA in Practice: Simplicity and Signal-Guided Strategy with PulseSelect – David Calvo Cuervo

  • 16:24: Redefining Focal Ablation in Our Clinical Practice With Affera Mapping and Ablation System – Jack McCready

  • 30:58: Audience Q&A – Reza Wakili, David Calvo Cuervo and Jack McCready

  • 35:22: Two Tools, One Toolkit: Case-Based Insights with PulseSelect and Sphere-9 – Verena Tscholl

  • 51:24: Panel Discussion – All

Chair Reza Wakili (Frankfurt, DE) leads a symposium with panellists David Calvo Cuervo (Madrid, ES), Verena Tscholl (Berlin DE) and Jack McCready (Worthing, UK). They focus on how pulsed field ablation is reshaping atrial arrhythmia workflows. David Calvo Cuervo presents a signal-guided pulmonary vein isolation strategy using the Medtronic PulseSelect system and FlexCath Cross transeptal solution, stressing catheter design, antral-first then ostial applications, confirmation of entrance and exit block, and efficient treatment of challenging anatomies such as a large left common trunk, with scope to extend to CTI and posterior wall ablation. Jack McCready shares early experience with the Affera mapping and ablation system using the SPHERE-9 lattice-tip catheter, which combines high-density mapping with dual-energy radiofrequency and pulsed field delivery. He reports single transeptal access, temperature-guided contact, rapid creation of roof, posterior wall, mitral and cavo-tricuspid isthmus lines, high acute block rates and shorter, day-case procedures under general anaesthetic, while addressing monitoring and coronary spasm considerations. Verena Tscholl then contrasts PulseSelect, used mainly for first-time PVI in paroxysmal and persistent atrial fibrillation, with Affera/SPHERE-9 for redo PVI, PVI-plus and ventricular tachycardia, highlighting low complication and haemolysis signals, encouraging durability, and efficient dual-energy lesion sets that support complex substrate ablation and increased lab throughput.

More 2025 Sessions On-Demand

Day 1 | Global

Day 2 | Global

Day 3 | US Focus

Day 4 | US Focus